Compare NHP & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NHP | MNKD |
|---|---|---|
| Founded | N/A | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2012 | 2004 |
| Metric | NHP | MNKD |
|---|---|---|
| Price | $16.60 | $4.10 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $8.69 |
| AVG Volume (30 Days) | 652.1K | ★ 4.4M |
| Earning Date | N/A | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 65.09 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $342,279,000.00 | ★ $348,966,000.00 |
| Revenue This Year | N/A | $35.81 |
| Revenue Next Year | N/A | $11.89 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 22.23 |
| 52 Week Low | $13.68 | $2.23 |
| 52 Week High | $17.46 | $6.51 |
| Indicator | NHP | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 57.64 | 52.91 |
| Support Level | $14.54 | $3.74 |
| Resistance Level | $17.22 | $4.27 |
| Average True Range (ATR) | 0.57 | 0.19 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 51.99 | 63.64 |
National Healthcare Properties Inc is a publicly registered real estate investment trust. It is focused on acquiring, owning, and managing a diversified portfolio of healthcare real estate assets focused on senior housing operating properties (SHOP) and outpatient medical facilities (OMF) in the United States. The company operates in two reportable business segments: SHOP and OMF. The SHOP segment consists of assisted living communities, memory care communities and independent living communities, which are focused on needs-based assisted living and memory care. The OMF segment consists of physicians' offices and examination rooms, hospitals, pharmacies, hospital ancillary service space and other outpatient services. The majority of revenue is derived from the SHOP segment.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.